AbbVie (NYSE: ABBV) details 2026 annual shareholder meeting vote outcomes

Q: When was AbbVie (ABBV) 2026 Annual Meeting of Stockholders held?

AbbVie’s 2026 Annual Meeting of Stockholders was held on May 8, 2026 . At this meeting, shareholders voted on director elections and several other proposals, with detailed for, against, abstain, and broker non-vote counts recorded for each item.

Q: How many votes did AbbVie (ABBV) director nominee Jennifer L. Davis receive?

Jennifer L. Davis received 1,216,558,754 votes for her election. She had 89,839,329 votes against, 2,680,369 abstentions, and there were 239,399,581 broker non-votes reported in connection with her director election item.

Q: What were the AbbVie (ABBV) vote results for director nominee Melody B. Meyer?

Melody B. Meyer received 1,284,771,578 votes for her election. The tally also shows 22,470,074 votes against, 1,836,800 abstentions, and 239,399,581 broker non-votes associated with this director election proposal at the 2026 annual meeting.

Q: How many votes did AbbVie (ABBV) director nominee Robert A. Michael receive in favor?

Robert A. Michael received 1,221,224,370 votes for his election as director. He had 85,865,852 votes against, 1,988,230 abstentions, and there were 239,399,581 broker non-votes reported on this voting item.

Q: What were the AbbVie (ABBV) vote totals for Frederick H. Waddell’s director election?

Frederick H. Waddell received 1,225,237,825 votes for his election. Shareholders cast 81,747,033 votes against, with 2,093,594 abstentions and 239,399,581 broker non-votes recorded for this director election proposal.

Q: Did any AbbVie (ABBV) proposal receive more than 1.5 billion votes in favor?

Yes. One proposal at AbbVie’s 2026 annual meeting received 1,522,575,012 votes for. The same proposal recorded 23,766,564 votes against and 2,136,457 abstentions, indicating a very large level of shareholder support by vote count.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

AbbVie Inc. reported the results of its 2026 Annual Meeting of Stockholders, held on May 8, 2026. Stockholders voted on the election of directors and several other matters.

Director nominees including Jennifer L. Davis, Melody B. Meyer, Robert A. Michael, and Frederick H. Waddell each received more than 1.21 billion votes in favor, with substantially fewer votes against or abstaining, alongside significant broker non-votes. Additional proposals received vote totals such as 1,522,575,012 for and 23,766,564 against on one item, and other items with for votes ranging from about 515.6 million to over 1.29 billion, all with recorded against, abstain, and broker non-vote counts.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Jennifer L. Davis: 1,216,558,754 votes Votes for Melody B. Meyer: 1,284,771,578 votes Votes for Robert A. Michael: 1,221,224,370 votes +5 more

8 metrics

Votes for Jennifer L. Davis 1,216,558,754 votes Director election at 2026 Annual Meeting

Votes for Melody B. Meyer 1,284,771,578 votes Director election at 2026 Annual Meeting

Votes for Robert A. Michael 1,221,224,370 votes Director election at 2026 Annual Meeting

Votes for Frederick H. Waddell 1,225,237,825 votes Director election at 2026 Annual Meeting

Large proposal for votes 1,522,575,012 votes For votes on one meeting proposal

Proposal against votes 23,766,564 votes Against votes on same proposal with 1.52B for

Proposal with lower for votes 515,626,009 votes For votes on another meeting item

Broker non-votes (several items) 239,399,581 votes Broker non-votes reported on multiple proposals

Key Terms

Annual Meeting of Stockholders, Broker Non-Votes, Emerging growth company, Senior Notes, +1 more

5 terms

Annual Meeting of Stockholders financial

"AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026."

Broker Non-Votes financial

"2,680,369 | | | 239,399,581 Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

Emerging growth company regulatory

"Emerging growth company AbbVie held its 2026 Annual Meeting"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Senior Notes financial

"Texas 0.750% Senior Notes due 2027 | | ABBV27"

Senior notes are a type of loan that a company borrows from investors, promising to pay it back with interest. They are called "senior" because in case the company faces financial trouble, these lenders are paid back before others. This makes senior notes safer for investors compared to other types of loans or bonds.

Common Stock, $0.01 Par Value financial

"Common Stock, $0.01 Par Value | | ABBV | | New York Stock Exchange"

Understanding 8-K Material Events →

05/12/2026 - 05:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2026

ABBVIE INC.

(Exact name of registrant as specified in its charter)

Delaware		001-35565		32-0375147
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 Par Value	ABBV	New York Stock Exchange
		NYSE Texas
0.750% Senior Notes due 2027	ABBV27	New York Stock Exchange
2.125% Senior Notes due 2028	ABBV28	New York Stock Exchange
2.625% Senior Notes due 2028	ABBV28B	New York Stock Exchange
2.125% Senior Notes due 2029	ABBV29	New York Stock Exchange
1.250% Senior Notes due 2031	ABBV31	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07

Submission of Matters to a Vote of Security Holders.

AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026. The following is a summary of the matters voted on at that meeting.

(1)	The stockholders elected AbbVie’s Class II directors with terms expiring in 2029, as follows:

Name	For	Against	Abstain	Broker Non-Votes
Jennifer L. Davis	1,216,558,754	89,839,329	2,680,369	239,399,581
Melody B. Meyer	1,284,771,578	22,470,074	1,836,800	239,399,581
Robert A. Michael	1,221,224,370	85,865,852	1,988,230	239,399,581
Frederick H. Waddell	1,225,237,825	81,747,033	2,093,594	239,399,581

(2)	The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026, as follows:

For			Against			Abstain
1,522,575,012			23,766,564			2,136,457

(3)	The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows:

For			Against			Abstain			Broker Non-Votes
1,228,615,745			69,336,359			11,126,348			239,399,581

(4)	The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:

For			Against			Abstain			Broker Non-Votes
1,290,990,023			14,896,119			3,192,310			239,399,581

(5)	The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows:

For			Against			Abstain			Broker Non-Votes
515,626,009			787,253,970			6,198,473			239,399,581

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ABBVIE INC.

Date:	May 12, 2026	By:	/s/ Perry C. Siatis
			Perry C. Siatis
			Executive Vice President, General Counsel and Secretary

Source: View Original Filing on SEC EDGAR

FAQ

When was AbbVie (ABBV) 2026 Annual Meeting of Stockholders held?

AbbVie’s 2026 Annual Meeting of Stockholders was held on May 8, 2026. At this meeting, shareholders voted on director elections and several other proposals, with detailed for, against, abstain, and broker non-vote counts recorded for each item.

How many votes did AbbVie (ABBV) director nominee Jennifer L. Davis receive?

Jennifer L. Davis received 1,216,558,754 votes for her election. She had 89,839,329 votes against, 2,680,369 abstentions, and there were 239,399,581 broker non-votes reported in connection with her director election item.

What were the AbbVie (ABBV) vote results for director nominee Melody B. Meyer?

Melody B. Meyer received 1,284,771,578 votes for her election. The tally also shows 22,470,074 votes against, 1,836,800 abstentions, and 239,399,581 broker non-votes associated with this director election proposal at the 2026 annual meeting.

How many votes did AbbVie (ABBV) director nominee Robert A. Michael receive in favor?

Robert A. Michael received 1,221,224,370 votes for his election as director. He had 85,865,852 votes against, 1,988,230 abstentions, and there were 239,399,581 broker non-votes reported on this voting item.

What were the AbbVie (ABBV) vote totals for Frederick H. Waddell’s director election?

Frederick H. Waddell received 1,225,237,825 votes for his election. Shareholders cast 81,747,033 votes against, with 2,093,594 abstentions and 239,399,581 broker non-votes recorded for this director election proposal.

Did any AbbVie (ABBV) proposal receive more than 1.5 billion votes in favor?

Yes. One proposal at AbbVie’s 2026 annual meeting received 1,522,575,012 votes for. The same proposal recorded 23,766,564 votes against and 2,136,457 abstentions, indicating a very large level of shareholder support by vote count.

Filing Exhibits & Attachments

4 documents